Revenue and Market Performance - The DoubleDown Casino game generated 76.1% of the company's revenue in 2025, down from 88.6% in 2024, indicating a need for diversification [36]. - Revenue from third-party platforms accounted for 79.8% of total revenue in 2025, a decrease from 90.0% in 2024, highlighting the importance of expanding direct payment channels [39]. - The average revenue per daily active user (ARPDAU) was $1.34 during 2025, indicating higher monetization compared to peers in the social casino sector [174]. - The global social casino market was estimated to be approximately $6.8 billion in 2025, with DoubleDown Casino ranked fifth among top game titles by revenue [173]. - The company reported a total revenue of $61 million from SuprNation for the year ended December 31, 2025, representing approximately 17% of total revenue for that year [178]. - SuprNation contributed $33 million in revenue for the year ended December 31, 2024, accounting for about 10% of total revenue for that year [178]. Player Engagement and Retention - The average monthly paying users (MPUs) for social casino games increased from 2024 to 2025, with the payer conversion rate rising from 6.7% to 8.2% [35]. - The average amount spent by paying players must be maintained or increased to sustain revenue levels, emphasizing the need for engaging content and incentives [35]. - The company's ability to attract and retain players is crucial, driven by the quality and quantity of games offered, necessitating continuous innovation and improvement [57]. - The company emphasizes the importance of high-quality support for players, as any failure in this area could adversely impact sales and financial results [59]. - The company releases new content every 1.5 to 2 weeks, enhancing player engagement and monetization opportunities [191]. - The Jackpot Happy Hour feature was introduced to DoubleDown Casino, resulting in higher wager levels and related purchases [190]. Legal and Regulatory Challenges - The company faces legal challenges regarding the classification of its social casino games, with ongoing lawsuits alleging illegal gambling practices [45]. - Regulatory scrutiny regarding consumer protection and gaming disorders could lead to increased operational costs and compliance requirements [47]. - The company is currently disputing a termination letter from IGT regarding its licenses to develop and distribute social casino game titles, asserting that the termination lacks legal basis [50]. - The company is cooperating with investigations from the Washington State Attorney General's Office regarding compliance with state gambling laws, which may incur additional legal expenses [64]. - The Washington State Gambling Commission has indicated that games involving virtual currency may constitute illegal gambling, prompting the company to review its compliance [65]. - The company may face additional legal proceedings or regulatory investigations in other states, which could restrict operations or require modifications to games [67]. - The company is subject to evolving laws and regulations across multiple jurisdictions, which could restrict operations and increase compliance costs [113]. - Compliance with iGaming regulations is costly and time-consuming, with potential for substantial fines and operational impacts if licenses are revoked or not obtained [74]. - Data privacy and security laws are evolving, increasing operational costs and legal exposure, particularly with the implementation of laws like the California Consumer Privacy Act (CCPA) [79]. - The European Union's General Data Protection Regulation (GDPR) imposes strict obligations on data handling, with potential fines of up to £17.5 million or 4% of total worldwide annual turnover for non-compliance [80]. - The company may face increased legal and financial compliance costs as a public reporting company, affecting its ability to attract and retain qualified board members [143]. Operational and Strategic Initiatives - Significant resources are allocated to research and development, analytics, and marketing to refresh existing games and launch new titles [36]. - The company plans to grow its player base through geographic expansion, particularly in Asia-Pacific and Western Europe, while managing the associated risks [33]. - The company has increased its research and development capabilities to create proprietary intellectual property, although there is no guarantee of market acceptance or timely development [50]. - The company intends to pursue selective mergers and acquisitions to enhance its capabilities and expand its geographic footprint [198]. - The company operates its social casino games and iGaming businesses on a robust technology infrastructure utilizing Amazon Web Services and Huawei Cloud for stable data management [218]. - A shared code base improves speed to market and minimizes development costs, enabling simultaneous updates across all games [220]. Competitive Landscape - The company operates in a highly competitive online gaming industry, characterized by rapid technological developments and changing player preferences [91]. - Competition for consumer discretionary spending is intense, with various leisure activities vying for players' attention [92]. - The company may face challenges in successfully integrating acquisitions, which could disrupt operations and limit growth [105]. - Economic downturns and global events, such as pandemics, could negatively impact consumer spending on entertainment and social casino games [106]. - High inflation rates in the U.S. and global markets may adversely affect the company's business and results of operations [107]. Financial and Shareholder Considerations - DoubleU Games holds approximately 67.1% of the company's shares, providing it with significant voting control over key decisions [131]. - The company does not currently intend to pay dividends on its common shares for the foreseeable future, as it plans to invest future earnings to fund growth [147]. - The company is obligated to pay royalties and license fees to DoubleU Games for approximately 49 slot titles actively offered to end users [139]. - The company is subject to certain loan agreements that could impede available working capital and adversely impact business operations and growth strategy [138]. - The company has not determined its status as a passive foreign investment company (PFIC), which could result in adverse tax consequences for U.S. investors [117]. Technology and Infrastructure - The company relies on third-party platforms for distribution, which poses risks if these platforms change their terms or face operational issues [40]. - The company relies on third-party information technology systems, and any failures could disrupt operations and impact financial results [98]. - Continuous creation of new and innovative games is deemed essential for attracting and retaining players and increasing market share [223]. - The company has a dedicated technology and content development team focused on expanding player reach with innovative games [223].

Drug Development and Clinical Trials - The company is developing two oral small molecule STAT3 inhibitors: TTI-101, currently in Phase 1b/2 clinical development for hepatocellular carcinoma (HCC), and TTI-109, a prodrug of TTI-101, with an IND application filed in June 2025[28][29]. - The anticipated data readout for the REVERT LIVER CANCER trial of TTI-101 has been extended to the second half of 2026 to allow for more mature data, including dose optimization and additional participant enrollment[29]. - Preliminary data from the REVERT IPF Phase 2 trial indicated that TTI-101 did not meet its primary goals, but further analysis showed reductions in fibrosis and inflammatory markers compared to placebo, supporting the mechanism of STAT3 inhibition[30][34]. - The ongoing Phase 1 trial of TTI-109 aims to confirm rapid pharmacokinetic conversion to TTI-101 and evaluate safety and tolerability[74]. - Topline data from the Phase 1 trial of TTI-109 is expected to be reported in the second quarter of 2026[75]. - The Phase 1b/2 clinical trial for TTI-101 aims to enroll up to 193 participants across 21 sites, evaluating safety and efficacy in various treatment cohorts[132]. - In the Phase 2 REVERT IPF clinical trial, 88 patients were randomized, with 58% receiving concomitant therapy; the placebo group had a discontinuation rate of 10.3%, while TTI-101 groups had rates of 56.7% and 62.1%[88][89]. - The decline in fibrosis score was greater in pooled patients treated with TTI-101 (-9.4%) compared to placebo (-2.4%) over 12 weeks[94]. - 63% of pooled patients treated with TTI-101 showed an increase in FVC at 12 weeks, compared to 46% in the placebo group[99]. - TTI-101 was well tolerated in a Phase 1 trial with no dose-limiting toxicities reported, and the most common treatment-related adverse event was diarrhea[119]. Mechanism of Action and Efficacy - The company's approach targets the persistent activation of STAT3, which is linked to chronic inflammation and proliferation, aiming to modulate key pathways simultaneously rather than targeting single pathways[42]. - Preclinical studies have shown that TTI-101 leads to dose-dependent decreases in targets associated with intrinsic proliferation and upregulation of markers related to extrinsic immune modulation[52]. - The company believes that direct targeting of STAT3 is a more robust approach compared to previous indirect methods, which often resulted in off-target effects and resistance[50][51]. - TTI-101 and TTI-109 are designed to inhibit STAT3 activation without impairing its essential mitochondrial functions, potentially leading to meaningful therapeutic benefits[51]. - TTI-101 demonstrated a 9.4% baseline-weighted reduction in fibrosis score in treated patients compared to a 2.4% reduction in the placebo group, indicating a 7 percentage point difference[69]. - TTI-101 demonstrated a statistically significant reduction in IL-6 levels, with a 4.5-fold greater decline compared to placebo, indicating its potential in treating fibrotic disorders[97]. - TTI-101 showed dose-dependent decreases in biomarkers associated with myofibroblast proliferation and ECM deposition, with p<0.05 for trend[59]. - TTI-101 demonstrated a median decrease of 55% in pY-STAT3 levels among patients, with a median decrease of 79% in those showing clinical benefit[120]. - The overall disease control rate for TTI-101 in advanced solid tumors was 54%, with a 53% disease control rate specifically in HCC patients[122]. - Among 41 evaluable patients, 12% achieved confirmed partial responses, while 41% had stable disease[123]. - A single patient with HCC showed a 66% reduction in tumor size after failing previous treatments, sustaining the response for 14 months[124]. Regulatory Designations and Intellectual Property - The FDA has granted Orphan Drug Designation for TTI-101 in both IPF and HCC, as well as Fast-Track Designation for TTI-101 in HCC[37]. - TTI-101 received Fast Track designation from the FDA, which may expedite its development process[139]. - The company plans to seek patent term extensions for its products upon FDA approval, which could provide additional market exclusivity[182][184]. - TTI-101 is protected by twelve patent families, with four in-licensed from BCM and seven owned by the company[166][171]. - The company has pending patent applications expected to expire on December 3, 2040, related to methods of using TTI-101 to treat insulin resistance[170]. - The company owns multiple patent families related to TTI-101 and TTI-109, with patents expected to expire between 2043 and 2046, indicating a strong intellectual property portfolio[176][177][178][179][180]. - The company has pending patent applications in various jurisdictions, including the U.S., Australia, Canada, and Europe, which could enhance its competitive position if granted[181][182]. Financial Obligations and Costs - The company paid a license fee of $75,000 to BCM and an annual maintenance fee of $30,000, which will increase to $50,000 before the introduction of a BCM1 Licensed Product[145]. - Upon initiation of Phase 2 clinical trials for two BCM1 Licensed Products, the company paid BCM development milestone payments totaling $250,000[146]. - The company expects to incur approximately $400,000 in oncology-related costs and $300,000 in non-oncology-related costs in connection with the Phase 3 clinical trial[146]. - The company is obligated to pay BCM royalties of a low-single-digit percent of net sales of BCM1 Licensed Products during the term of the license[145]. - The company paid a license execution fee of $5,000 for the BCM2 Licensed Products and is required to pay royalties of a low-single-digit percent of net sales[152]. - The company anticipates one-time milestone payments of up to $1,225,000 for the first BCM2 Licensed Product upon achieving specified development and regulatory milestones[152]. Market and Competitive Landscape - The company faces substantial competition from larger pharmaceutical companies and smaller biotech firms, emphasizing the need for effective differentiation in product development[187][188]. - The company is aware of several approved and investigational products in its target disease areas, which could impact market entry and pricing strategies[189][194]. - The incidence of HCC is projected to reach 42,000 new cases in the U.S. in 2024, highlighting a significant unmet medical need[105]. - The company intends to commercialize its product candidates independently or with partners once they receive marketing approval, highlighting a flexible commercialization strategy[191]. FDA Approval Process - The FDA approval process is lengthy and resource-intensive, requiring extensive preclinical and clinical testing before a drug can be marketed[196][197][198]. - The FDA has set a review goal of 10 months for standard NDAs and 6 months for priority review applications from the 60-day filing date[216]. - Orphan Drug Designation is granted for drugs intended to treat rare diseases affecting fewer than 200,000 individuals in the U.S., providing exclusivity for seven years upon FDA approval[220][221]. - The FDA may require Phase 4 post-marketing studies to monitor safety and efficacy after product approval[206][218]. - Clinical trial sponsors must register and disclose trial information on www.clinicaltrials.gov, including results after completion[223]. - The FDA reviews applications to ensure products are safe and effective, with inspections of manufacturing facilities and clinical trial sites[215]. - Changes to approved products, such as new indications, require prior FDA review and approval[225]. - Investigational drugs must be manufactured in compliance with cGMP requirements to ensure quality and safety[208][209]. - The FDA may impose additional post-marketing requirements based on the results of Phase 4 studies or safety surveillance[218][224]. - Sponsors must provide annual progress reports to the FDA detailing clinical trial results and any serious adverse events[207]. Operational Strategy - The company relies on third-party Contract Development and Manufacturing Organizations (CDMOs) for both preclinical studies and potential commercial manufacturing, indicating a strategy to mitigate operational risks[192][193]. - The company currently has no sales or marketing capabilities but plans to build these over time as product candidates advance through clinical development[190].

IPO and Regulatory Approvals - The company received approval from the China Securities Regulatory Commission (CSRC) for its initial public offering on September 25, 2023, and its Class A ordinary shares are listed on the Nasdaq Stock Market since January 25, 2024[32]. - On September 25, 2023, the CSRC approved the company's initial public offering under the new regulations, with Class A ordinary shares listed on Nasdaq starting January 25, 2024[139]. - The company does not currently fall under any prohibitive circumstances for overseas offerings as outlined by the CSRC[141]. Strategic Restructuring and Subsidiary Sales - The company entered into agreements for the sale of ten wholly-owned subsidiary companies for an aggregate consideration of US$100,000 as part of a strategic restructuring to optimize its business portfolio[37]. - The company also sold trademark portfolios for an aggregate consideration of US$50,000, bringing the total consideration for the transactions to US$150,000[37]. - As of December 31, 2025, the company entered into agreements for the sale of ten wholly-owned subsidiary companies for an aggregate consideration of $100,000, as part of a strategic restructuring[223]. - The operational control and management rights of Proimage B.V. have been transferred to the purchaser, although the equity transfer is still in process[223]. - The company does not expect the disposition of subsidiaries to have a material adverse impact on its ongoing business operations[223]. Financial Performance and Revenue - Revenue for the years ended December 31, 2023, 2024, and 2025 amounted to approximately US$150.2 million, US$149.8 million, and US$155.2 million, respectively, with a gross profit margin of approximately 39.3%, 34.9%, and 29.4%[92]. - Total cash received from other subsidiaries by Jiangxi Yibo for the fiscal year ended December 31, 2023, was US$43,933,578, increasing to US$69,904,017 in 2024, and projected to be US$79,255,778 in 2025[41]. - Revenue generated from Russia was US$6.3 million, US$3.5 million, and nil for the years ended December 31, 2023, 2024, and 2025, representing 4.2%, 2.3%, and nil of total revenues, respectively[117]. - Revenue from Eastern Europe was US$13.6 million, nil, and nil for the same years, representing 9.1%, nil, and nil of total revenue, respectively[117]. - Revenue from online retail stores was approximately US$11.4 million, US$12.9 million, and US$15.2 million for the fiscal years ended December 31, 2023, 2024, and 2025, respectively, accounting for 7.6%, 8.6%, and 9.8% of total revenue[104]. Cash Flow and Dividends - The Cayman Islands holding company has not declared or paid dividends in the past and does not plan to do so in the foreseeable future, relying instead on price appreciation for returns[44]. - The company may face limitations on dividend distributions from its Mainland PRC subsidiaries due to PRC regulations, which require profits to be distributed only from accumulated profits[144]. - The company is subject to a 10% withholding tax on dividends paid by its Mainland PRC subsidiary to foreign investors, which could increase tax liabilities and reduce available cash[144]. - The company’s Mainland PRC subsidiaries are required to set aside at least 10% of after-tax profits for statutory reserves, which are not distributable as cash dividends[144]. Risks and Challenges - The company faces risks from potential changes in the legal and regulatory environment in China, which could materially affect its operations and the value of its securities[28]. - The company may face delisting risks under the Holding Foreign Companies Accountable Act if the PCAOB cannot inspect its auditor for two consecutive years[35]. - The company faces risks related to the rapid technological development in the compatible toner cartridge market, which may impact customer retention and acquisition[55]. - The company faces foreign exchange risks as a substantial portion of revenue is derived in US$ and Euro, while costs are mostly in RMB, potentially impacting profit margins[80]. - A downturn in the global economy due to geopolitical tensions could materially adversely affect the company's business and financial condition[118]. Operational and Market Conditions - The operating subsidiaries plan to expand their global reach through increased sales and marketing efforts and further geographical market expansion[76]. - The operating subsidiaries operate six overseas subsidiaries in the U.S., the Netherlands, Italy, Germany, the United Kingdom, and France, with 47 foreign employees as of December 31, 2025[76]. - The operating subsidiaries face intense competition in the compatible toner cartridge industry, which may impact their market position and financial performance[74]. - The company is increasing purchases from suppliers located near production facilities to mitigate future supply chain risks[117]. Compliance and Regulatory Environment - The company is subject to stringent labor laws in European countries where it operates, which may increase compliance costs and affect operational flexibility[83]. - Compliance with PRC regulations for mergers and acquisitions by foreign investors is complex and time-consuming, potentially hindering growth through acquisitions[157]. - The company may face challenges in complying with the Cybersecurity Review Measures, which could limit its ability to offer securities and affect its financial position[167]. - Evolving policies and unclear official guidance may lead to additional compliance requirements in the future, impacting the company's operations[168]. Intellectual Property and R&D - As of December 31, 2025, the operating subsidiaries owned 409 registered patents and 122 trademarks across various regions, indicating a strong intellectual property portfolio[56]. - The company aims to deliver high-quality and cost-effective printing solutions globally through proprietary technology and R&D capabilities[227]. - The company has over 400 registered patents in the U.S., Europe, and China related to the manufacture of compatible toner cartridges[216]. Employee and Labor Relations - The operating subsidiaries had a total of 665 employees for manufacturing as of December 31, 2025, with a total of 1,615 full-time employees, including 37 located in European countries[83]. - The PRC Labor Contract Law, enacted in 2008, mandates unlimited-term contracts for employees after ten consecutive years, potentially increasing labor costs[154]. - Mainland PRC subsidiaries did not make adequate contributions to social insurance and housing funds for certain employees during 2023, 2024, and 2025, but received confirmations from local authorities that no penalties were imposed[155]. Market Volatility and Shareholder Concerns - The trading price of Class A ordinary shares is likely to be volatile, influenced by market factors and company-specific operations, leading to potential substantial losses for investors[184]. - Share price volatility may be exacerbated by low trading volumes, which can cause significant price fluctuations and affect liquidity for shareholders[188]. - Analysts' recommendations significantly influence the market price of Class A ordinary shares; downgrades or loss of coverage could lead to price declines[193]. - The concentration of ownership among Class B shareholders may discourage changes in control that could benefit Class A shareholders, potentially affecting share value[191].

Drug Development and Clinical Trials - Connect Biopharma is advancing rademikibart, a next-generation antibody targeting IL-4Rα for asthma and COPD treatment[21]. - The Phase 2 trials for rademikibart initiated in May 2025 aim to evaluate treatment failure over 28 days post-randomization[25]. - In January 2026, new data indicated rademikibart's rapid improvement in FEV, with many patients showing improvements of ≥200 mL as early as 15 minutes post-dosing[27]. - Rademikibart demonstrated mean FEV improvements of approximately 200-400 mL maintained through Day 29 in asthma and COPD patients[27]. - The global Phase 2b trial of rademikibart demonstrated significant improvement in lung function, with a 140 ml (p = 0.005) increase in FEV for the 150 mg group and a 189 ml (p < 0.001) increase for the 300 mg group at Week 12 compared to placebo[36]. - Improvements in asthma control were noted, with absolute placebo-adjusted changes in ACQ-6 score at Week 24 of -0.33 (p < 0.01) for the 300 mg group and -0.44 (p < 0.001) for the 150 mg group[36]. - In patients with baseline eosinophils >150 cells/µL, the 150 mg group showed a statistically significant reduction in exacerbations (p = 0.023)[36]. - Rademikibart was well-tolerated, with low incidences of adverse events such as injection site reactions (1.8%) and conjunctivitis (3.5%) reported[44]. - The company has only one Product Candidate, rademikibart, currently in clinical development, and has invested substantially all efforts and financial resources into its development[195]. - The company may need to conduct additional clinical trials if it fails to obtain accelerated approval, increasing development costs and delaying commercialization[194]. - The ability to recruit competent clinical trial investigators and maintain patient consents is crucial for the success of clinical trials[182]. - Regulatory authorities may suspend or terminate clinical trials due to various factors, including failure to comply with regulatory requirements[170]. - The company has engaged CROs to conduct clinical trials outside the U.S., including in Ukraine, but the ongoing Russia-Ukraine war has impacted trial progress[172]. - The company may experience delays in patient enrollment for clinical trials, which could adversely affect research and development efforts[176]. - Serious adverse events associated with Product Candidates could lead to interruptions or halts in clinical trials and regulatory approval[179]. - The company must comply with evolving regulatory requirements, such as the EU Clinical Trials Regulation, which may impact development plans[175]. - Delays in clinical trials could shorten the exclusive commercialization period for Product Candidates, allowing competitors to enter the market sooner[174]. - The company has never submitted an NDA or BLA and may face challenges in obtaining regulatory approvals for its Product Candidates[203]. - The regulatory approval processes by the FDA and NMPA are lengthy and unpredictable, typically taking many years after the commencement of clinical trials[204]. - The company has not obtained regulatory approval for any Product Candidates in the U.S. or other jurisdictions, which may hinder future development[205]. - Approval policies and regulations may change during clinical development, potentially affecting the approval process for Product Candidates[206]. - The FDA and NMPA can delay or deny approval for various reasons, including disagreements on clinical trial design and unexpected side effects[207]. Market Opportunities and Financials - Asthma affects approximately 23 million adults and 5 million children in the U.S., with 50% of patients failing to improve on first-line treatments[22]. - COPD impacts around 14.2 million adults in the U.S., with 85% of patients not improving on initial therapies[23]. - The AD market in China represents a significant opportunity, with an estimated 70 million patients affected[30]. - Rademikibart's development plan focuses on addressing unmet needs in acute asthma and COPD, targeting approximately 1 million and 1.3 million patients visiting emergency departments annually[28]. - The company incurred net losses of $55.5 million and $15.6 million for the years ended December 31, 2025 and 2024, respectively, with an accumulated loss of $400.8 million as of December 31, 2025[153]. - The company expects to continue incurring significant losses for the foreseeable future as it conducts ongoing and planned preclinical studies and clinical trials[153]. - The company anticipates that additional capital will be required to fund product development and commercialization efforts[155]. - The company has an effective shelf registration statement covering the offering of up to $300 million in securities, including up to $150 million of ordinary shares[164]. - The company’s ability to raise additional capital may cause substantial dilution to shareholders and restrict operations[164]. - The company’s future financing requirements will depend on various factors, including the progress and results of clinical trials and regulatory reviews[160]. Regulatory Environment - The FDA requires extensive regulatory compliance for drug approval, including the submission of an Investigational New Drug (IND) application[66]. - Clinical trials are divided into three phases, with Phase 1 focusing on safety and dosage, Phase 2 on preliminary efficacy, and Phase 3 on larger population testing[76]. - The NDA or BLA submission requires comprehensive data from clinical trials and payment of a substantial application user fee to the FDA[75]. - The FDA requires an initial pediatric study plan to be submitted within 60 days after an end-of-Phase 2 meeting for any NDA or BLA that includes a new active ingredient or indication[77]. - The FDA aims to review standard applications within 10 months and priority reviews within 6 months after filing, with possible extensions for major amendments[78]. - Approval of an NDA or BLA is contingent upon compliance with cGMP requirements and successful inspections of manufacturing facilities[79]. - The FDA may issue a Complete Response Letter (CRL) detailing deficiencies in the NDA or BLA, which could require additional clinical trials or labeling changes[80]. - Orphan drug designation can be granted for drugs intended to treat rare diseases affecting fewer than 200,000 individuals in the U.S., providing potential exclusivity benefits[88]. - Products with orphan drug designation may receive exclusivity for 7 years if they are the first to be approved for the designated condition[89]. - The FDA offers expedited programs like fast track and breakthrough therapy designations to accelerate the development and review of qualifying product candidates[82][84]. - Pediatric exclusivity can provide an additional 6 months of exclusivity if clinical trials in children are conducted in response to an FDA request[99]. - The FDA imposes ongoing regulatory requirements post-approval, including record-keeping and reporting of adverse experiences[92]. - Non-compliance with FDA regulations can lead to severe consequences, including product recalls and withdrawal of approval[93]. - The Biologics Price Competition and Innovation Act (BPCIA) allows biosimilar applications to be submitted to the FDA four years after the reference product's first licensing, with a 12-year exclusivity period for the reference product[101]. - The ACA increased Medicaid rebates for brand-name drugs from 15.1% to 23.1%, impacting pricing strategies for pharmaceutical manufacturers[119]. - The Inflation Reduction Act of 2022 implements significant changes to the Medicare program, including drug pricing reforms[123]. - The EU's HTA Regulation, effective from January 2025, aims to provide a transparent framework for health technology assessments, influencing pricing and reimbursement decisions[118]. - Third-party payors are increasingly reducing reimbursements for pharmaceutical products, which may limit sales and affect physician usage[114]. - The U.S. government and state legislatures are implementing cost-containment programs, including price controls and restrictions on coverage, impacting market dynamics[114]. - The approval process for pharmaceutical products varies significantly across countries, with no assurance that FDA approval will lead to foreign approvals[103]. - The federal Anti-Kickback Statute imposes strict regulations on remuneration practices, with potential criminal and civil penalties for violations[105]. - The Physician Payments Sunshine Act requires annual reporting of certain payments to healthcare providers, adding compliance complexity for manufacturers[110]. - The BPCIA allows biosimilars to rely on previous FDA determinations of safety and effectiveness, potentially reducing approval costs and time[100]. - The IRA imposes inflation rebates on drug manufacturers if prices increase faster than inflation, starting in 2023, and caps Medicare Part D out-of-pocket spending at $2,000 beginning in 2025[124]. - The OBBBA enacted in July 2025 is expected to decrease Medicaid enrollment and services, potentially impacting sales of commercialized products[125]. - The Trump administration's proposed Globe and Guard regulations could require drug manufacturers to pay rebates based on most favored nation pricing, significantly affecting the pharmaceutical sector[126]. - States in the U.S. are implementing regulations for pharmaceutical pricing transparency, which may include price limits on certain drugs[127]. - Future healthcare reforms may lead to stricter coverage criteria and downward pressure on prices received for approved products[128]. Intellectual Property and Patents - As of December 31, 2025, the company holds over 93 issued patents and has more than 50 pending patent applications globally[54]. - The patent family for rademikibart includes two granted U.S. patents and over 28 foreign patents, with expected expiration in 2037 and 2040 for different formulations[55]. - The company intends to pursue patent protection for composition, method of use, process, dosing, and formulation for its Product Candidates[57]. - Patent terms typically last 20 years from the earliest filing date, with potential extensions under the Hatch-Waxman Act for FDA-approved drugs of up to five years[56]. - The company may submit provisional patent applications to the USPTO, which must be followed by non-provisional applications within 12 months[58]. - The Patent Cooperation Treaty (PCT) allows for a single application to be filed within 12 months of the original priority date, enabling protection in multiple member states[59]. - The company continuously reassesses its patent portfolio to ensure maximum coverage and value for its processes and compositions[61]. - There is no assurance that the company will be able to obtain or maintain all necessary patents and intellectual property rights[62]. - The company may rely on trade secrets to protect proprietary information that is not suitable for patent protection[63]. Company Operations and Workforce - The company has 64 full-time employees as of December 31, 2025, with 38 in research and development and 26 in general administration[141]. - The equity incentive plan aims to attract and retain employees through share-based compensation awards[142]. - The company offers competitive compensation and benefits, including a 401(k) plan, health insurance, and an employee stock purchase plan[143]. - The company does not own manufacturing facilities and relies on third-party contract manufacturers for production[50]. - The Foreign Investment Law of the PRC governs investment activities by non-PRC investors, impacting the company's operations in China[136]. - The company is subject to various financial disclosure and securities trading regulations as a public entity, including SEC oversight[140]. - The company has incurred significant costs associated with operating as a public company and expects these costs to continue[157]. - The company maintains most of its cash and cash equivalents in accounts with major financial institutions, which may exceed insured limits[163]. - The company faces risks related to the lengthy and expensive clinical drug development process, which may incur unforeseen costs or delays[168]. - The company relies on third parties for conducting preclinical studies and clinical trials, which may impact the ability to obtain regulatory approval if not managed properly[217]. - Compliance with GCP and cGMP regulations is critical; failure to do so may require repeating clinical trials and delay the approval process[218]. - Clinical sites and CROs have the right to terminate agreements under certain conditions, which could adversely affect the company's clinical trials[220].

Drug Development Pipeline - The company has a pipeline of seven drug candidates, including ENV 105 and ENV 205, targeting significant unmet needs in prostate and lung cancer markets, with the global prostate cancer therapeutics market valued at USD 7.9 billion and EGFR mutant non-small cell lung cancer at USD 1.7 billion[25]. - ENV 105 has shown a clinical benefit rate of 62% in a Phase 2 trial involving heavily pre-treated prostate cancer patients, indicating disease stabilization or regression[25]. - The Phase 2 trial for ENV 105 is being conducted at multiple centers, including Cedars-Sinai, University of Utah, and City of Hope, focusing on patients resistant to standard hormone therapies[31]. - The company initiated three clinical trials in the fall of 2023 for KROS 201 and ENV 105, with ENV 105 targeting both cancer cells and their supportive non-cancer environment to address resistance mechanisms[24]. - KROS 101, a small molecule targeting the GITR ligand, is in pre-IND studies and aims to enhance the antitumor immune response by depleting regulatory T cells[39]. - ENV 205 is designed to target elevated mitochondrial DNA in circulation, which is associated with chemotherapy resistance and aims to restore chemotherapy sensitivity while reducing side effects[33]. - The company is developing KROS 102, KROS 301, and KROS 401, which target various mechanisms of immune suppression at the tumor site[32]. - KROS 201 is an activated T cell therapy targeting glioblastoma, with the market for T cell therapy expected to grow from $4.9 billion in 2021 to $20.8 billion by 2030, reflecting a CAGR of 20.4%[62]. - ENV 105 is in a Phase 2 clinical trial for prostate cancer patients resistant to androgen-targeted therapy, with a potential market of $9 billion for a six-month dose in the U.S. alone[58]. - ENV 205 has shown promise in preclinical studies for limiting chemotherapy-resistant prostate cancer, with the chemotherapy market for docetaxel projected to grow from $137 billion in 2024 to $329 billion by 2033[55]. - KROS 301 is in active preclinical development, targeting the NF-kB pathway, with the global small-molecule cancer therapies market valued at $175.3 billion in 2021[63]. - KROS 401 is a cyclic peptide in preclinical development, with the global peptide therapeutics market size estimated at $117.3 billion in 2024, expected to grow at a CAGR of 10.77%[64]. - The global immune checkpoint inhibitor market size was $47.4 billion in 2023 and is anticipated to reach $189.1 billion by 2032, with a CAGR of 16.7% from 2024 to 2032[61]. - ENV 205 is positioned to address cachexia, a condition affecting 50% of cancer patients, with the specific cancer cachexia therapeutics market projected to grow from over $2 billion in 2022 to over $4 billion by 2032[65]. Clinical Trials and Regulatory Challenges - The company aims to develop innovative therapeutics targeting drug resistance and immune suppression in cancer treatment, with a focus on advancing its clinical pipeline[67]. - The company plans to complete enrollment in a Phase 2 trial of ENV 105 for prostate cancer and a Phase 1 trial for non-small cell lung cancer patients on Tagrisso[67]. - The time required to obtain regulatory approval is unpredictable and typically takes many years, influenced by various factors including the discretion of regulatory authorities and government funding levels[130]. - The company has not submitted a marketing application for any product candidates in any country or region, which is a lengthy and uncertain process requiring extensive data to establish safety and efficacy[133]. - Only a small percentage of drugs in development successfully complete the FDA approval process and are commercialized, posing a significant risk to the company's business and financial condition[134]. - Even if regulatory approval is obtained, it may be contingent on the performance of additional costly clinical trials, which could limit the approved indications or patient populations[145]. - The company relies on third-party contract research organizations for regulatory application support, which may introduce additional risks due to limited experience in this area[129]. - Regulatory approval processes may change during clinical development, impacting the ability to commercialize products in a timely manner[131]. - The company must demonstrate that its product candidates are safe and effective, which requires extensive preclinical and clinical studies that can be costly and time-consuming[139]. - Delays in clinical trials can occur due to various factors, including regulatory requirements, patient recruitment challenges, and unforeseen safety issues[141]. - The company faces significant risks related to the potential for negative clinical trial results, which could prevent obtaining regulatory approval or achieving market acceptance[138]. - Delays in clinical trials could harm the commercial prospects of product candidates and increase costs, potentially allowing competitors to market their products first[147]. - Future regulations from authorities like the FDA may increase the time and cost required for clinical trials, impacting the ability to obtain marketing approvals[148]. - The company has limited experience in designing and implementing clinical trials, which could lead to increased costs and delays in obtaining regulatory approvals[156]. - Serious adverse events (SAEs) or undesirable side effects identified during development could lead to the discontinuation of clinical programs or limitations on product use, affecting commercial potential[150]. - Positive results from early clinical trials may not predict future outcomes, and there is a high failure rate for drugs in clinical development[154]. Financial and Operational Considerations - The company has incurred significant losses since inception and expects to continue incurring losses over the next several years, with no products approved for commercial sale[118]. - The company requires substantial additional funding to meet financial needs and pursue business objectives, with future capital requirements dependent on various factors[119]. - The company has limited operating history, making it difficult to evaluate its prospects for achieving business objectives and commercial success[123]. - The company may face dilution of stockholder ownership if additional capital is raised through equity offerings or debt financings[121]. - The company is committed to employee development, offering competitive compensation and benefits to attract and retain skilled personnel[112]. - The company lacks a sales or marketing infrastructure and limited experience in the sale, marketing, or distribution of pharmaceutical products[200]. - Establishing sales, marketing, and distribution capabilities will require substantial resources and could delay product launches[200]. - Market acceptance of approved product candidates will depend on various factors, including the size of the target market[199]. - Coverage and adequate reimbursement from third-party payors are critical for the commercial success of any product candidates[203]. Patent and Intellectual Property - The company holds multiple patents related to cancer treatment, including compositions and methods for treating cancer and autoimmune diseases, with expiration dates ranging from 2037 to 2040[91][92][93]. - The patent for "Sensitization of Tumors to Therapies through Endoglin Antagonism" is currently in application status in Australia and Canada, with a protection date until June 14, 2037[91][92]. - The company holds a patent for "Method of Generating Activated T Cells for Cancer Therapy," which is set to expire on August 10, 2040 in Canada[91]. - The patent portfolio includes compositions for treating diseases by depletion of mitochondrial or genomic DNA from circulation, with a protection date until November 25, 2040 in Canada[91]. - The company has secured patents in multiple jurisdictions, including China, Europe, and Japan, for various cancer treatment methods and compositions[92][93]. - The patent for "Antibody Formulations and Uses Thereof" is granted in India and Japan, with an expiration date of September 5, 2033[93]. - The company has a granted patent for treating fibrosis, which is applicable in France, Germany, Switzerland, and the United Kingdom, expiring on September 18, 2035[93]. - The patent for "Compositions and Methods for Treating Cancer and Autoimmune Diseases" is granted in Japan, with a protection date until August 8, 2039[93]. - The company is actively pursuing new technologies and methods for cancer treatment, as evidenced by its extensive patent applications and granted patents[91][92][93]. - The company’s patent strategy indicates a strong focus on innovative cancer therapies, positioning it well for future market opportunities[91][92][93]. Acquisitions and Corporate Structure - The company acquired Enviro Therapeutics, Inc. in June 2021, enhancing its pipeline with advanced drug candidates in Phase 1 and Phase 2 trials[21]. - Kairos Pharma conducted a 1-for-2.5 reverse stock split on May 10, 2023, resulting in 10,334,357 shares of common stock outstanding[98]. - The company acquired AcTcell Biopharma, issuing 5,045,000 shares for all outstanding shares of AcTcell[99]. - The acquisition of AcTcell was treated as a transaction under common control, recognizing the historical cost basis of AcTcell's assets and liabilities[100]. - Kairos acquired Enviro in a share exchange, issuing 6,000,000 shares of restricted common stock, representing approximately 20% of the outstanding shares on a fully diluted basis[102]. - Following the Enviro-Kairos share exchange, Kairos had approximately 19,825,957 shares of common stock issued and outstanding on a fully diluted basis[103]. - Effective April 17, 2025, Kairos assumed all responsibilities and liabilities of Enviro under existing agreements, leading to Enviro's dissolution[104]. Market and Economic Factors - The global cancer drug spending was valued at approximately $232 billion in 2024 and is expected to reach $532 billion by 2031, driven by targeted therapies and immuno-oncology[56]. - The healthcare industry's trend towards cost containment may impact the demand and pricing of drugs, affecting commercialization efforts[205]. - The company faces risks associated with international marketing, including differing regulatory requirements and potential economic instability in foreign markets[212]. - The company is exposed to product liability claims that could result in substantial liabilities and limit commercialization of its products[208]. - The company may not be able to obtain adequate product liability insurance coverage, which could adversely affect its operations and share price[209]. - The reliance on single-sourced third parties for clinical trials and manufacturing may lead to delays if those parties fail to perform satisfactorily[215]. - The company must navigate various risks related to compliance with healthcare laws and regulations, which could result in significant penalties and reputational harm[214].

Technology and Product Development - Co-Diagnostics, Inc. has developed a proprietary PCR test design technology called Co-Primers®, which significantly reduces false positives in PCR amplification [20]. - The Co-Dx PCR Pro instrument and associated mobile application are designed for point-of-care and at-home testing, providing results in approximately 30 minutes [27]. - The company has designed tests for genetic traits in plant and animal genomes, demonstrating the versatility of its Co-Primers technology beyond infectious disease detection [25]. - The molecular diagnostics market is rapidly growing, with PCR tests offering higher specificity and sensitivity compared to other diagnostic methods, positioning the company favorably in this segment [44]. - The company has a competitive advantage through affordability, flexibility, speed, and accuracy of its tests, which are designed for various diagnostic testing machines [50]. - The company’s proprietary Co-Primers technology is protected by multiple patents, with recent patents granted in Australia and Japan for its Co-Dx PCR platform [51]. - The company has established a joint venture with CoSara Diagnostics in India to expand its manufacturing and development capabilities for PCR tests [31]. - The company has established a joint venture, CoMira Diagnostics, in Saudi Arabia to develop and commercialize Co-Dx technologies across 18 countries in the MENA region, aligning with Saudi Vision 2030 [40]. Regulatory Approvals and Compliance - Co-Diagnostics has obtained regulatory clearance for PCR diagnostic tests for various diseases, including COVID-19, influenza, and tuberculosis, in multiple countries, including the U.S., U.K., and India [24]. - The company has received EUA clearance for its Logix Smart COVID-19 test, allowing sales to qualified labs in the U.S. and facilitating international registrations [41]. - The company has received CE markings for six tests, including COVID-19 and tuberculosis, and is actively pursuing compliance under the new In Vitro Diagnostic Regulation (IVDR) with a grace period until 2029 for Class B devices [38]. - The company operates under an ISO 13485:2016 certified quality management system, facilitating regulatory clearance applications [56]. - The FDA's 510(k) clearance process typically takes one to six months, but the premarket approval (PMA) process can take two to three years, significantly delaying commercialization [80]. - The company must comply with numerous healthcare laws and regulations, which could expose it to civil penalties and reputational harm if found in violation [83]. Financial Performance - For the year ended December 31, 2025, total revenue decreased by 84% to $622,489 compared to $3,915,160 in 2024, primarily due to a significant drop in grant revenue [158]. - Product revenue fell by 46% to $418,205 in 2025 from $770,048 in 2024, reflecting lower demand and grant revenue recognition [158]. - Gross profit decreased by 86% to $400,112 in 2025, down from $2,916,036 in 2024, attributed to lower revenue levels [158]. - The company reported a net loss of $46,895,936 for the year ended December 31, 2025, a 25% increase from the net loss of $37,639,008 in 2024 [158]. - Total operating expenses increased by 18% to $50,565,464 in 2025, compared to $42,997,346 in 2024, mainly due to an impairment charge of $18.9 million related to in-process research and development [158]. - Cash and cash equivalents were reported at $11.9 million as of December 31, 2025 [72]. - The accumulated deficit of the company was $80.4 million as of December 31, 2025, compared to $33.5 million in 2024 [61]. Funding and Capital Structure - The company entered into a new Equity Distribution Agreement allowing for an aggregate offering price of up to $10.0 million [73]. - The company sold 151,675 shares under the previous ATM Agreement, resulting in net proceeds of approximately $1.66 million [72]. - The company completed a registered direct offering of 320,634 shares at $12.00 per share in September 2025, generating gross proceeds of approximately $3.8 million [174]. - A second registered direct offering in October 2025 raised approximately $7.0 million from the sale of 400,076 shares at $16.50 per share [177]. - Future financing efforts may lead to dilution of existing stockholders' interests and could restrict operations or require relinquishing proprietary rights [76]. Legal and Compliance Risks - The company is currently involved in two securities class action claims and three derivative actions, which may negatively impact its reputation and financial condition [101]. - The company has received a notice from NASDAQ indicating that its common stock bid price has closed below the minimum $1.00 per share required for continued listing, with an initial 180-day period to regain compliance [112]. - A reverse stock split of 1-for-30 was executed to regain compliance with the $1.00 minimum bid price requirement, reducing the number of outstanding shares from approximately 62.9 million to approximately 2.1 million [114]. - The company faces significant competition from larger firms with established customer bases and greater financial resources [63]. - The company faces risks related to intellectual property litigation, which could result in substantial costs and harm its financial resources and reputation [99]. Operational Challenges - The company relies on a limited number of third-party suppliers for key raw materials, which poses risks to production [65]. - The company must expand its product lines to include new diagnostic products to achieve future success [66]. - The company has not entered into employment agreements with its senior management team, which could impact business strategy execution [69]. - The company incurs significant costs as a public company, which may divert management's attention from product development and commercialization activities [110]. - The company has implemented cybersecurity processes based on NIST frameworks to manage risks associated with cybersecurity threats [118]. - There have been no material internal or external cybersecurity incidents reported to date, and no known risks are expected to materially affect the business strategy or financial condition [122]. Market Position and Future Outlook - The company anticipates leveraging its established distribution network built over the past six years for future sales of diagnostic tests and its forthcoming PCR diagnostic platform [43]. - The company focuses on developing and marketing advanced diagnostics technologies, particularly for nucleic acid detection and analysis [214]. - The company faces substantial doubt about its ability to continue as a going concern due to recurring losses from operations, which may require liquidation of assets [75]. - The company is classified as a "smaller reporting company," which may make its common stock less attractive to some investors due to reduced disclosure requirements [107]. - The market price of the company's common stock may fluctuate substantially due to various factors, including regulatory approvals and competition [102].

Expansion and Growth Strategy - In 2025, GEN Inc. expanded its footprint with partnerships with grocery stores, offering ready-to-cook meals at over 800 locations, with plans to expand to 1,500 to 2,500 locations in 2026[21]. - As of December 31, 2025, GEN Inc. operated 57 company-owned restaurants across various states and South Korea, with plans to open 18 new locations by the end of 2026[21][26]. - The company opened 15 new restaurants in 2025 and six new restaurants in 2024, indicating a focus on expansion[58]. - As of December 31, 2025, the company operated restaurants in eleven states, including California, Arizona, and Texas, and plans to increase the number of restaurants in the coming years[62]. - The average AUV for new restaurant units is targeted to range from $4.0 million to $5.0 million, contributing to the goal of a Payback Period of less than three years[28]. Financial Performance and Costs - The average Payback Period for new restaurants opened in 2022 was approximately 1.9 years, resulting in an average ROI of over 50%, while restaurants opened in 2023 and 2024 had a Payback Period of approximately 2.2 years and an ROI of about 45%[22]. - The average Net Build-Out Costs for new restaurants opened in 2023 and 2024 were approximately $2.1 million and $2.2 million, respectively, with a target of less than $3.0 million going forward[28]. - In 2024 and 2025, food costs as a percentage of sales increased from 33.0% to 34.6%, while payroll and benefits costs as a percentage of sales decreased from 30.9% to 30.4%[57]. - Sysco accounted for approximately 57.4% of food costs, while two third-party vendors accounted for 32.5% of total food costs[35]. - The company initiated a modest price increase in late 2024 and again in February 2026, with no discernible change in guest behavior, indicating potential for further price increases without impacting customer traffic[29]. Workforce and Employment - GEN Inc. employs approximately 2,700 individuals, with 375 in full-time positions, and has a workforce that is 37% female and 63% male[41]. - The company may face challenges in hiring and retaining qualified employees in new markets, which could impact operational success[63]. - Labor costs are a primary component of operating expenses, and increases in minimum wage, particularly in California, could adversely affect the company's financial condition and results of operations[131]. - Labor shortages and increased competition for employees could lead to higher labor costs, adversely affecting the company's growth and operating results[124]. Risks and Challenges - The company may face challenges in opening new restaurants within budget or on time due to various uncertainties, which could adversely affect financial performance[58]. - Inflationary pressures on food, labor, and utilities are expected to continue impacting the business through 2026, potentially affecting revenues and results of operations[57]. - The company has identified risks related to competition, consumer preferences, and spending patterns in new markets, which may affect profitability[63]. - The company faces significant risks related to supply chain disruptions, which could lead to increased costs and shortages of food items[89]. - Economic conditions, including unemployment and consumer confidence, significantly influence consumer discretionary spending, impacting restaurant traffic[69]. Legal and Compliance Issues - The company is currently involved in class action lawsuits regarding workplace and employment conditions, which may result in substantial damages[146]. - The company faces risks related to compliance with federal and state laws, which could lead to civil or criminal penalties and damage its reputation[143]. - Adverse publicity from litigation or noncompliance could materially affect GEN Inc.'s business and financial results[148]. - The company is subject to various employment-related claims, which could materially affect its ability to compete and its financial condition[130]. Tax and Financial Obligations - GEN Inc. anticipates future payments under the Tax Receivable Agreement to total approximately $99.6 million based on an assumed Class A common stock price of $12.00 per share[155]. - Payments under the Tax Receivable Agreement will be based on tax savings realized from increases in tax basis and are expected to be substantial, potentially affecting liquidity[154]. - The company may need to incur debt to finance payments under the Tax Receivable Agreement if distributions from GEN LLC are insufficient[155]. - Future changes in tax laws could materially affect the company's financial position and overall tax rates, reducing post-tax returns to stockholders[164]. Operational Risks - The company has experienced material weaknesses in internal control over financial reporting, which have been remediated as of December 31, 2024[59]. - The company faces potential increased occupancy costs due to long-term non-cancelable leases, which could materially impact its business if restaurants are not profitable[119]. - The company may experience difficulties in obtaining necessary licenses and permits, which could delay new restaurant openings and adversely affect existing operations[136]. - Mechanical failures of restaurant equipment could disrupt operations and lead to significant unplanned capital investments[107]. Market and Competitive Landscape - The restaurant industry is highly competitive, with significant competition from national and regional chains, as well as local establishments, impacting the company's financial condition and operations[93]. - The presence of "all you can eat" Asian restaurants near the company's locations could negatively affect sales and profitability[94]. - Comparable restaurant sales change, representing year-over-year sales for restaurants open for at least 18 months, is critical for sales growth[75]. - The company may experience sales cannibalization as new restaurants open in proximity to existing locations[71]. Technology and Data Compliance - The company relies on various information technology systems for operations, and any inadequacy or failure of these systems could disrupt business and result in transaction errors[215]. - Compliance with privacy and data protection laws is complex and varies by jurisdiction, posing risks to the company's operations[218]. - The California Consumer Privacy Act (CCPA) and California Privacy Rights Act (CPRA) may require substantial compliance costs and could lead to increased litigation risks[219]. - Implementation of new information technology systems in 2025 may involve risks such as data loss and disruption of normal business operations[216].

IPO and Financing - The company completed its initial public offering on February 24, 2026, raising gross proceeds of $125,150,000 from the sale of 12,500,000 units at $10.00 per unit, plus an additional 15,000 units from the underwriters' over-allotment option [23]. - A private sale of 315,000 private units was completed simultaneously, generating gross proceeds of $3,150,000 [24]. - The total proceeds of $125,150,000 from the IPO and private placement were placed in a trust account maintained by Equiniti Trust Company, LLC [26]. - The company has $125,150,000 available for a business combination, assuming no further exercise of the over-allotment or redemptions [64]. - The company has approximately $1,737,000 of proceeds held outside the trust account to fund costs associated with the dissolution plan [97]. - The net proceeds from the initial public offering and private placement of units amount to approximately $1.737 million, which will be used for working capital and to complete the initial business combination [180]. Business Combination Strategy - The management team aims to target financial services businesses with strong management, differentiated products, and clear pathways to long-term profitability [21]. - The company intends to focus on private companies with positive operating cash flow or compelling economics, significant assets, and successful management teams [36]. - The acquisition strategy emphasizes leveraging extensive networks and relationships to identify unique opportunities in the financial services sector [33]. - The company plans to seek target companies that exhibit rapid growth and business innovation, particularly in the highest growth segments of the financial services industry [38]. - The management team has significant experience in identifying and capitalizing on emerging trends, particularly in the financial services sector [30]. Shareholder Rights and Redemption - The company will provide public shareholders the opportunity to redeem shares upon the completion of the initial business combination, allowing for flexibility in shareholder participation [47]. - Public shareholders will have the opportunity to redeem up to 15% of the shares sold in the initial public offering at a price of approximately $10.00 per share, based on the trust account balance [81]. - If the initial business combination is not completed within the completion window, 100% of public shares will be redeemed at approximately $10.00 per share [49]. - The company will restrict public shareholders from seeking redemption rights for Excess Shares without prior consent, limiting the ability to block the business combination [86]. - If the initial business combination is not completed, public shareholders who elected to redeem their shares will not be entitled to redeem for the trust account's pro rata share [92]. Risks and Challenges - The lack of business diversification may pose risks as the company may depend entirely on the performance of a single business post-combination [65]. - The company may face conflicts of interest due to management's ownership of founder shares and private units [57]. - The company may face increased competition for attractive business combination targets as the number of special purpose acquisition companies rises [124]. - The search for a business combination may be adversely affected by external factors such as geopolitical unrest and market volatility [1]. - The company may face challenges in completing its initial business combination within the specified completion window, which could limit due diligence and negotiation time with potential target businesses [135]. Regulatory and Compliance Issues - Nasdaq rules require that the business combination must have an aggregate fair market value of at least 80% of the assets held in the trust account [50]. - Shareholder approval will be sought for business combinations that require it under applicable law or stock exchange rules [70]. - The company is classified as an "emerging growth company," allowing it to take advantage of certain exemptions from reporting requirements, including reduced disclosure obligations [117]. - The company may face regulatory review and approval requirements for its initial business combination, particularly from CFIUS, which could limit the pool of potential targets [197]. - Compliance with the Sarbanes-Oxley Act may increase the time and costs of completing an initial business combination, particularly if the target business is not compliant with internal control provisions [200]. Management and Personnel - The company currently has two executive officers, with no full-time employees expected prior to the completion of the initial business combination [112]. - Key personnel's efforts are critical for the success of the initial business combination, and their potential loss could negatively impact operations and profitability [213]. - Employment or consulting agreements for key personnel may create conflicts of interest in determining the most advantageous business combination [214]. - The loss of key personnel from an acquisition candidate upon completion of the business combination could adversely affect the post-combination business [216]. - The company may not maintain control of a target business after the initial business combination, potentially leading to management that lacks necessary skills for profitable operation [217]. Financial Projections and Obligations - The anticipated redemption price for public shares in connection with the initial business combination is expected to be $10.00 per share, including interest earned on funds held in the trust account [107]. - The company may need to seek additional financing to complete its initial business combination if the cash portion of the purchase price exceeds available funds, which could lead to restructuring or abandonment of the transaction [193]. - The company is facing increased obligations to repay indebtedness if certain financial covenants are breached, which could limit cash flow available for dividends and other corporate purposes [183]. - The company may face risks from combining with financially unstable businesses, which could adversely affect operations and shareholder value [175]. - The company may attempt to complete multiple business combinations simultaneously, which could increase costs and risks [182].

IPO and Fundraising - The company completed its initial public offering (IPO) on January 16, 2025, raising total gross proceeds of $50,000,000 by selling 5,000,000 units at an offering price of $10.00 per unit[22]. - A total of $50,000,000 from the IPO and private placement was placed in a U.S.-based trust account for the benefit of public shareholders[24]. - The company has approximately $50,000,000 available for a business combination, which can be used for liquidity events, growth capital, or debt reduction[64]. - The company intends to use substantially all net proceeds from the IPO and private placement for its initial business combination and related expenses[151]. - The company may seek additional funds through private offerings of debt or equity securities to complete the initial business combination[67]. Business Combination Plans - The company entered into a Business Combination Agreement with DRC Medicine Inc., DRC Medicine Ltd., and DRC Merger Inc. on June 30, 2025, and is focused on completing this proposed business combination[18]. - The company has 12 months from the closing of the offering to consummate an initial business combination, with the possibility of seeking shareholder approval for an extension[46]. - The initial business combination must involve target businesses with an aggregate fair market value of at least 80% of the balance in the trust account at the time of signing a definitive agreement[44]. - The company anticipates structuring the initial business combination to acquire 100% of the equity interests or assets of the target business, but may acquire less than 100% under certain conditions[47]. - If the company cannot complete the proposed business combination, it may continue to evaluate alternative business combination opportunities[48]. Financial Performance and Position - The company reported a net income of $690,218 for the year ended December 31, 2025, with operating expenses of $1,258,096 and income from marketable securities of $1,948,314[149]. - As of December 31, 2025, the company had $11,497 in cash and a working capital deficit of $556,173[152]. - The company has not generated any revenue to date and has incurred losses since inception due to formation and operating costs[147]. - The company has not paid any cash dividends and does not intend to do so prior to completing its initial business combination[133]. - The company has incurred approximately $14.9 million in redemptions from the trust account, reducing available funds for business combinations to about $10.40 per share[155]. Management and Governance - The management team has extensive experience in cross-border mergers and acquisitions, capital raising, and investment, which is expected to aid in identifying attractive acquisition targets[28]. - The management team believes that their ability to assess potential target companies will enhance the likelihood of successful public listings[31]. - The company has adopted a Code of Ethics applicable to its directors, officers, and employees, which will be available for review in public filings[204]. - The audit committee includes independent directors who are financially literate, with Mr. Chris Constable qualifying as an "audit committee financial expert"[195][198]. - The corporate governance and nominating committee oversees the selection of nominees for the board of directors, considering qualifications such as management experience and integrity[199][200]. Regulatory and Compliance Issues - The company does not currently hold any equity interest in any PRC company or operate any business in China, thus believes no permission is required from PRC governmental authorities for its operations or offerings[43]. - Any uncertainties regarding regulatory approvals from PRC authorities could materially affect the trading price of the company's securities[43]. - The company will comply with Regulation M and other federal securities laws for any private purchases made by its affiliates[86]. - The company will not complete the business combination if the cash required for redemptions exceeds the available cash in the trust account[97]. - The company is classified as an "emerging growth company" and will remain so until it has total annual gross revenue of at least $1.235 billion or meets other criteria[62]. Shareholder Rights and Redemption - Public shareholders will have the opportunity to redeem their shares at a per-share price equal to the aggregate amount in the trust account divided by the number of outstanding public shares[88]. - If shareholder approval is required, a public shareholder can only seek redemption rights for a maximum of 15% of the shares sold in the offering, referred to as "Excess Shares"[98]. - The tender offer for redemptions will remain open for at least 20 business days, and the company cannot complete the initial business combination until the tender offer period expires[91]. - Shareholders must exercise their redemption rights to receive funds from the trust account in connection with the initial business combination[116]. - The expected per-share redemption amount upon dissolution is approximately $10.00, subject to potential increases of up to $0.10 if the sponsor extends the business combination period[111]. Risks and Challenges - The company may face intense competition from other entities with similar business objectives, including blank check companies and private equity groups[49]. - There is a risk that the company may depend on the performance of a single business post-combination, limiting diversification[75]. - Management has raised substantial doubt about the Company's ability to continue as a going concern due to significant professional and transaction costs[154]. - The company’s board may face conflicts of interest in determining appropriate business combination targets due to affiliations with its Sponsor and directors[209]. - The company’s officers and directors owe fiduciary duties to the entities they are affiliated with, which may affect their obligations to the company[213].

IPO and Fundraising - The company completed its initial public offering (IPO) on January 16, 2025, raising total gross proceeds of $50 million by selling 5,000,000 units at an offering price of $10.00 per unit[22]. - A total of $50 million from the IPO and private placement was placed in a U.S.-based trust account for the benefit of the company's public shareholders[24]. - The company has approximately $50,000,000 available for a business combination, which can be used for liquidity events, growth capital, or debt reduction[64]. - The company generated gross proceeds of $50,000,000 from its IPO by selling 5,000,000 units at $10.00 per unit[136]. - A total of $50,000,000 from the IPO and private placement was placed in a trust account, which will be invested in U.S. government treasury bills or money market funds[150]. - The company intends to use substantially all net proceeds from the IPO and private placement for its initial business combination and related expenses[151]. Business Combination Plans - The company entered into a Business Combination Agreement with DRC Medicine Inc., DRC Medicine Ltd., and DRC Merger Inc. on June 30, 2025, and is currently focused on completing this proposed business combination[18]. - The company plans to focus on acquiring private companies with strong growth prospects and clear paths to positive operating cash flow[34]. - The company has 12 months from the closing of the offering to consummate an initial business combination, with the possibility of seeking shareholder approval for an extension[46]. - The initial business combination must involve target businesses with an aggregate fair market value of at least 80% of the balance in the trust account at the time of signing a definitive agreement[44]. - If the proposed business combination is not completed, the company may continue to evaluate alternative business combination opportunities[48]. - The company anticipates that the post-transaction entity will own or acquire 100% of the equity interests or assets of the target business[47]. - The company may seek additional funds through private offerings of debt or equity securities to complete the initial business combination[67]. - If the initial business combination is funded with assets other than trust account assets, shareholder approval may be required depending on the financing terms[68]. - The company intends to conduct thorough due diligence on prospective target businesses, including financial and operational reviews[73]. Financial Performance and Condition - The company has no revenue and has incurred losses since inception, relying on the sale of securities and loans to fund operations[26]. - The company had a net income of $690,218 for the year ended December 31, 2025, consisting of operating expenses of $1,258,096 and income from marketable securities of $1,948,314[149]. - As of December 31, 2025, the company had $11,497 in cash and a working capital deficit of $556,173[152]. - The company has not generated any revenue to date and has incurred losses since inception due to organizational and operating costs[147]. - The company has not paid any cash dividends and does not intend to do so prior to completing its initial business combination[133]. - Management has raised substantial doubt about the Company's ability to continue as a going concern due to significant professional and transaction costs[154]. Governance and Management - The management team has extensive experience in cross-border mergers and acquisitions, capital raising, and investment, which is expected to aid in identifying attractive acquisition targets[28]. - The company is classified as an "emerging growth company" and will remain so until it has total annual gross revenue of at least $1.235 billion or meets other criteria[62]. - The company is also a "smaller reporting company," allowing it to provide reduced disclosure obligations until certain market value and revenue thresholds are met[63]. - The company has adopted a Code of Ethics applicable to directors, officers, and employees, which will be disclosed in public filings[204]. - The corporate governance and nominating committee oversees the selection of nominees for the board, considering qualifications such as management experience and integrity[199][200]. - The audit committee includes independent directors who are financially literate, with Mr. Chris Constable qualifying as an "audit committee financial expert" as per SEC rules[195][198]. - The compensation committee is responsible for reviewing and approving the compensation of the Chief Executive Officer and other officers, ensuring alignment with corporate goals[203][206]. Shareholder Rights and Redemption - Public shareholders will have the opportunity to redeem their shares at a per-share price equal to the aggregate amount in the trust account divided by the number of outstanding public shares[88]. - The company will not redeem public shares if it would cause net tangible assets to fall below $5,000,001, ensuring compliance with SEC regulations[97]. - If shareholder approval is required, a public shareholder can only seek redemption rights for a maximum of 15% of the shares sold in the offering, referred to as "Excess Shares"[98]. - The tender offer for redemptions will remain open for at least 20 business days, and the company cannot complete the business combination until the tender offer period expires[91]. - The expected per-share redemption amount upon dissolution is approximately $10.00, subject to potential increases of up to $0.10 if the sponsor extends the business combination period[111]. - Shareholders must exercise their redemption rights to receive funds from the trust account, which will only occur upon completion of the business combination or other specified events[116]. Risks and Uncertainties - The company may face intense competition from other entities with similar business objectives in identifying and completing a business combination[49]. - Any uncertainties regarding regulatory approvals from PRC authorities could materially affect the trading price of the company's securities[43]. - There is a risk that the company may depend on the performance of a single business post-combination, limiting diversification[75]. - The company’s board may face conflicts of interest in determining appropriate business combination targets due to affiliations with its Sponsor and directors[209]. - The company’s officers and directors owe fiduciary duties to the entities they are affiliated with, which may affect their obligations to the company[213]. Internal Controls and Compliance - Management assessed the effectiveness of internal controls and found material weaknesses due to inadequate segregation of duties and insufficient policies[171]. - The audit committee is tasked with reviewing and approving all audit services and related-party transactions, ensuring compliance with applicable laws[196][201]. - The company has not identified any critical accounting policies or estimates that could materially differ from actual results[159]. - There were no changes in internal control over financial reporting that materially affected the Company during the most recent fiscal quarter[173].